[Theranostics for glioblastoma with monoclonal antibodies to the epidermal growth factor receptor]

Area of Science:

• Oncology
• Immunotherapy
• Molecular Diagnostics

Background:

• Multiform glioblastoma is an aggressive brain tumor with limited treatment options.
• Epidermal growth factor receptor (EGFR) is a validated therapeutic target in various cancers.
• Monoclonal antibodies targeting EGFR have shown potential in cancer treatment.

Purpose of the Study:

• To review the prospects of theranostics for multiform glioblastoma utilizing monoclonal antibodies against EGFR.
• To identify the challenges and limitations in applying EGFR-targeted theranostics to glioblastoma treatment.

Main Methods:

• Literature review of studies on EGFR-targeted therapies and theranostics in glioblastoma.
• Analysis of the current status and future potential of monoclonal antibodies against EGFR for glioblastoma.

Main Results:

• EGFR-targeted monoclonal antibodies have demonstrated significant potential in treating various malignancies.
• The effectiveness of these antibodies in glioblastoma is currently limited.
• A key constraint is the absence of reliable criteria for assessing diagnostic and therapeutic effectiveness.

Conclusions:

• EGFR-targeted theranostics offer a promising avenue for multiform glioblastoma treatment.
• Development of informative biomarkers and assessment criteria is crucial for successful clinical translation.
• Further research is needed to overcome current limitations and optimize EGFR-targeted theranostics for glioblastoma.